The Impact of the Consciousness Energy Healing Treated Test Formulation on Vital Organs Health Biomarkers

Joy Angevin Balmer, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana

Find on Google Scholar

---

Abstract

The study was performed to find out the impact of the Biofield Energy Treated test formulation on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Joy Angevin Balmer, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The Biofield Energy Treated medium (BT-Med) + Biofield Treated test item (UT-TI) group showed 149.3% restoration of cell viability at 1 µg/mL as compared to the UT-Med + UT-TI group in human cardiac fibroblasts cells (HCF). Moreover, the UT-Med + BT-TI and BT-Med + BT-TI groups showed 54.2% (at 0.1 µg/mL) and 43.5% (at 63 µg/mL) restoration of cell viability, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 58.3% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI group at 0.1 µg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 92.4%, 72.1%, and 87.4% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 64.7% (at 25 µg/mL) and 87.9% (at 50 µg/mL) in the BT-Med + BT-TI group in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 163% and 80.6% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 0.1 µg/mL compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 89.3% and 60.4% at 1 µg/mL in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 61.1% (at 1 µg/mL) and 43.5% (at 63 µg/mL) in the BT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to untreated in A549 cells. Serotonin level was significantly increased by 32.5% and 34.2% in the BT-Med + BT-TI group at 10 and 63 µg/mL, respectively as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 174.4% (at 10 µg/mL), 212% (at 1 µg/mL), and 196.1% (at 0.01 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.

---

---